VANCOUVER, British Columbia, Jan. 14, 2019 (GLOBE NEWSWIRE) -- Nash Pharmaceuticals Inc., a wholly owned
subsidiary of Breathtec Biomedical Inc. (CSE: BTH) (CNSX: BTH) (FRANKFURT: BTI) (OTCQB: BTHCF) (the
“Company” or “Nash Pharma”) is pleased to announce that in a new recent in vivo animal study for
Chronic Kidney Disease (CKD), the activity of NP-135 was confirmed, and two additional compounds, NP-160 and NP-251 were
identified as new lead compounds in a unilateral ureteral obstruction (UUO) mouse model of kidney fibrosis.
Data from this study demonstrated that clinically relevant doses resulted in statistically significant
improvements in the reduction in fibrosis in the UUO model as measured by Sirius Red staining over untreated controls:
- Telmisartan (3mg/kg), a positive control, reduced fibrosis by 32.6% (p<0.001)
- Cenicriviroc (40 mg/kg) a CCR2/5 chemokine receptor antagonist with reported anti-fibrotic activity, reduced
fibrosis by 31.9% (p=0.00032).
- NP-135 (200 mg/kg) reduced fibrosis by 52.1% (p<0.000001). In addition, the mass of the fibrotic kidney was
lower than the negative control (i.e. closer to normal, p=0.016).
- NP-160 (40 mg/kg) reduced fibrosis by 57.6% (p <0.000001). NP-160 was also previously reported to be
anti-fibrotic in a mouse model of non-alcoholic steatohepatitis (NASH).
- NP-251 (90 mg/kg) reduced fibrosis by 50.6% (p<0.000001) with evidence of slight synergy (54.2% reduction in
fibrosis, p<0.000001) when a low dose (30 mg/kg, 20.8% reduction in fibrosis, p>0.05) was combined with the same dose of
Telmisartan (3mg/kg). In addition, the mass of the fibrotic kidney was lower than the negative control (p<0.001).
“This additional study not only validated our original discovery of NP-135 but has also identified NP-160 and
NP-251 as additional leads for the treatment of CKD”, said Christopher J. Moreau CEO of Nash Pharma. “We look forward to updating
the market with additional information on these and other compounds shortly”
About Chronic Kidney Disease (“CKD”)
CKD is a condition in which the kidneys are damaged or cannot filter blood as well as healthy kidneys, often as
a result of fibrosis. Because of this, excess fluid and waste from the blood remain in the body and may cause other health
problems.
The global market for CKD drugs continues to proliferate at a significant pace, driven by the increasing number of CKD patients and
the growing need of novel treatments to improve patients’ quality of life. The global CKD drug market stood at US$11.5 Billion in
2015. Burgeoning at a CAGR of 3.60% between 2016 and 2024, the market’s opportunity is expected to reach US$15.8 Billion by the end
of 2024.
About Nash Pharmaceuticals Inc.
Nash Pharma is a wholly owned subsidiary of Breathtec Biomedical Inc. Nash Pharma is a clinical stage
pharmaceutical development company focused on drug repurposing in the areas of non–alcoholic steatohepatitis (NASH), chronic kidney
disease (CKD) and inflammatory bowel disease (IBD). Drug repurposing is the process of discovering new therapeutic uses for
existing drugs. Repurposing offers several benefits over traditional drug development including a reduction in investment
and risk, shorter research periods and a longer active patent life.
For more information, visit https://nashpharmaceuticals.com/.
CONTACT INFORMATION
Christopher J. Moreau
CEO
Nash Pharmaceuticals Inc.
604.398.4175 ext 701
info@breathtechbiomedical.com
investors@breathtecbiomedical.com
www.breathtecbiomedical.com
The CSE does not accept responsibility for the adequacy or accuracy of this
release.
Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the
Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. The Canadian Securities Exchange
has not in any way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this
press release.
CAUTIONARY DISCLAIMER STATEMENT: No Securities Exchange has reviewed nor accepts responsibility for the
adequacy or accuracy of the content of this news release. This news release contains forward-looking statements relating to product
development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts.
Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar
expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that
involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and
future events could differ materially from those anticipated in such statements. Important factors that could cause actual results
to differ materially from the Company’s expectations include the failure to satisfy the conditions of the relevant securities
exchange(s) and other risks detailed from time to time in the filings made by the Company with securities regulations. The reader
is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or
circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks,
uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue
reliance on any forward-looking information. Such information, although considered reasonable by management at the time of
preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements
contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in
this news release are made as of the date of this news release and the Company will update or revise publicly any of the included
forward-looking statements as expressly required by applicable law.
